Travere Therapeutics, Inc.(TVTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,149 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in TVTX
Events flagged as statistical outliers against TVTX's own multi-year baseline — not fixed dollar thresholds.
TVTX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Travere Therapeutics, Inc. (TVTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVTX at 56.6/100 on a 32-signal composite quality model, placing it at rank #1,149 of 2,962 stocks — the top half of the AI-ranked universe. TVTX scores in the top quartile across revenue growth (96.1), earnings quality (84.9). Areas of concern include balance sheet strength (20.6) and profitability (29.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Travere Therapeutics, Inc. reports quarterly revenue of $169.6M, net income of $-34.8M. Top institutional holders of TVTX by reported 13-F value include Jupiter Topco, BlackRock, FMR, based on the most recent SEC filings. TVTX trades on the Nasdaq exchange and files with the SEC under CIK 1438533. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Travere Therapeutics, Inc. directly from SEC EDGAR. Travere Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 13 and 57 since 2021, currently 56.6 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$169.6M
Net Income
Q2 2026
$-34.8M
ROIC
Q2 2026
64.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+110.5% YoYNet Income
+92.1% YoYOperating Income
+80.6% YoYEPS (Diluted)
+92.9% YoYTotal Assets
+1.9% YoYOp. Cash Flow
+115.9% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $490.7M +110.5% | $233.2M +60.5% | $145.2M +32.7% | $109.5M -17.0% | $131.8M -33.5% | $198.3M |
| Net Income | $-25.5M +92.1% | $-321.5M -188.6% | $-111.4M +60.0% | $-278.5M -54.6% | $-180.1M -6.3% | $-169.4M |
| Operating Income | $-62.8M +80.6% | $-323.8M +16.6% | $-388.1M -21.4% | $-319.8M -60.4% | $-199.4M -13.2% | $-176.2M |
| EPS (Diluted) | $-0.29 +92.9% | $-4.08 -172.0% | $-1.50 +65.7% | $-4.37 -45.2% | $-3.01 +15.4% | $-3.56 |
| Total Assets | $605.2M +1.9% | $594.1M -24.7% | $788.9M +17.3% | $672.6M -13.4% | $776.6M +27.9% | $607.4M |
| Operating Cash Flow | $37.8M +115.9% | $-237.5M +15.2% | $-280.0M -50.3% | $-186.3M -1159.4% | $-14.8M +65.4% | $-42.7M |
| Free Cash Flow | — | — | $-280.7M -50.5% | $-186.5M -837.4% | $-19.9M +59.8% | $-49.5M |
Get alerted when TVTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Travere Therapeutics, Inc. including:
Top Institutional Holders of TVTX
Jupiter Topco LLC
$643.3M11,324,191 shBlackRock, Inc.
$455.7M8,020,663 shFMR LLC
$403.2M7,096,614 shBANK OF AMERICA CORP /DE/
$259.5M4,568,341 shSTATE STREET CORP
$241.8M4,256,224 shVANGUARD CAPITAL MANAGEMENT LLC
$233.4M4,108,694 shPERCEPTIVE ADVISORS LLC
$213.2M3,752,574 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$159.8M2,812,514 shADAGE CAPITAL PARTNERS GP, L.L.C.
$146.0M2,569,356 shGEODE CAPITAL MANAGEMENT, LLC
$134.8M2,371,887 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $643.3M | 11,324,191 |
| BlackRock, Inc. | $455.7M | 8,020,663 |
| FMR LLC | $403.2M | 7,096,614 |
| BANK OF AMERICA CORP /DE/ | $259.5M | 4,568,341 |
| STATE STREET CORP | $241.8M | 4,256,224 |
| VANGUARD CAPITAL MANAGEMENT LLC | $233.4M | 4,108,694 |
| PERCEPTIVE ADVISORS LLC | $213.2M | 3,752,574 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $159.8M | 2,812,514 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $146.0M | 2,569,356 |
| GEODE CAPITAL MANAGEMENT, LLC | $134.8M | 2,371,887 |
Companies Similar to TVTX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xeris Biopharma Holdings, Inc.
iRhythm Holdings, Inc.
Tarsus Pharmaceuticals, Inc.
BridgeBio Pharma, Inc.
Mirum Pharmaceuticals, Inc.
BIOCRYST PHARMACEUTICALS INC
PTC THERAPEUTICS, INC.
Immunocore Holdings plc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TVTX on your watchlist
Track score changes the day Travere Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TVTX a good stock to buy?
13F Pro's AI-powered analysis of Travere Therapeutics, Inc. (TVTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TVTX are available on the TVTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TVTX is classified as a mid company.
Which hedge funds own TVTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TVTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Travere Therapeutics, Inc.'s investment landscape.